A Pilot Study of Olaparib and Durvalumab in Patients With Metastatic Triple Negative Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Jul 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Olaparib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 12 Jul 2019 According to NCT, inclusion criteria states Frontline patients who have not received prior systemic therapy and who have received =< 2 prior chemotherapy regimens.Since, info is not clear about progression, so second-line is not added in patient segement for now. Pls update further.
- 05 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2018 New trial record